Evidence map›Paper›PMID 36864461›Full record

ArticleJournal of nanobiotechnology2023

Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression.

Yunhao Wang, Genjiang Zheng, Xiaoxing Xie, Wei Yu, Jianxi Wang, Fazhi Zang, Chen Yang, Qiangqiang Xiao, Rongcheng Zhang, Leixin Wei and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Yunhao Wang *Spine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Genjiang Zheng *Spine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Xiaoxing Xie *Spine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Wei Yu *Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
Jianxi WangSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Fazhi ZangSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Chen YangSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Qiangqiang XiaoSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Rongcheng ZhangSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Leixin WeiSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Xiaodong WuSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Lei LiangSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Peng CaoSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Chen XuSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Jing LiSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Bo HuSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. hubomed@163.com.
Tao ZhangDepartment of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. zhangtao012345678@126.com.
Jinglei WuShanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China. jw@dhu.edu.cn.
Huajiang ChenSpine Center, Department of Orthopedics, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. spine_czchenhj@163.com.
Shanghai Changzheng Hospital · CNDonghua University · CNSecond Military Medical University · CNShanghai Jiao Tong University · CNShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intervertebral disc degeneration (IDD) has been identified as one of the predominant factors leading to persistent low back pain and disability in middle-aged and elderly people. Dysregulation of Prostaglandin E2 (PGE2) can cause IDD, while low-dose celecoxib can maintain PGE2 at the physiological level and activate the skeletal interoception. Here, as nano fibers have been extensively used in the treatment of IDD, novel polycaprolactone (PCL) nano fibers loaded with low-dose celecoxib were fabricated for IDD treatment. In vitro studies demonstrated that the nano fibers had the ability of releasing low-dose celecoxib slowly and sustainably and maintain PGE2. Meanwhile, in a puncture-induced rabbit IDD model, the nano fibers reversed IDD. Furthermore, low-dose celecoxib released from the nano fibers was firstly proved to promote CHSY3 expression. In a lumbar spine instability-induced mouse IDD model, low-dose celecoxib inhibited IDD in CHSY3

Indexed as

DinoprostoneIntervertebral Disc DegenerationAnimalsCelecoxibDisease Models, AnimalMicePolyestersRabbitsCelecoxibDinoprostonepolycaprolactonePolyestersCHSY3Intervertebral disc degenerationLow-dose celecoxibPGE2

Identifiers

PMID36864461
PMCPMC9983215
OpenAlexW4323036367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.